| Symbol | LOBEF |
|---|---|
| Name | LOBE SCIENCES LTD. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6G 3B7 Canada BC 1771 Robson Street #1614 |
| Telephone | +1 949-505-5623 |
| Fax | — |
| — | |
| Website | https://www.lobesciences.com/ |
| Incorporation | CA |
| Incorporated On | 2010 |
| Employees | — |
| Fiscal Year | 8/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Davidson & Company LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | — |
| Description | Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally. Additional info from OTC: |
No news found.